Crossmark

ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2022-005527

Published Online: 2023-02-23

Published Print: 2023-02

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Chen, Huanhuan

Yang, Keqing

Pang, Lingxiao

Fei, Jing

Zhu, Yongliang https://orcid.org/0000-0001-7450-885X
Zhou, Jianwei
Funding

Funding for this research was provided by:

Natural Science Foundation of Zhejiang Province (LY20H160028)

National Natural Science Foundation of China (81902633)

Key Research and Development Program of Zhejiang Province of China (2020C03013)
License Information

License valid from 2023-02-23